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Abstract Only few prospective longitudinal studies have
assessed the course of intelligence deficits in early onset
schizophrenia (EOS), and these have used different age
appropriate versions of Wechsler Intelligence Scales and
age appropriate norms. The post-psychotic development of
intelligence in EOS has predominantly been characterized as
relatively stable in these studies. However, comparisons of
IQs from different test versions based on the different norms
may not permit unequivocal interpretations. The objective
of the current study was to compare the development of
intelligence in EOS patients (N = 10) from their first psy-
chotic episode to 5 years of post onset with that of healthy
controls (N = 35) and patients who at baseline had been
diagnosed with other non-affective psychoses (N = 8). The
same version of a Wechsler Intelligence Scale was admin-
istered at both baseline and follow-up assessments, and the
same norms were used to derive IQs at baseline and follow-
up. Significantly smaller change in mean full scale
intelligence quotient (FSIQ) was found in diagnostically
stable EOS patients compared with healthy controls during
the follow-up period. However, no statistically significant
difference in mean FSIQ change was observed between
patients with EOS and patients with other non-affective
psychoses, although this result must be interpreted with
caution due to the small sample sizes. The results suggest
abnormally slow acquisition of new intellectual information
and skills in EOS patients during the first 5 years after full
clinical presentation.
Keywords Intelligence  IQ  Longitudinal  Adolescent 
Schizophrenia  Early onset psychosis
Introduction
Very few prospective longitudinal studies have examined the
course of intelligence deficits in early onset schizophrenia
(EOS; onset before age 18). Early onset schizophrenia is
associated with premorbid impairments in intelligence [16],
speech development, social functioning, and academic per-
formance [1, 51]. In addition, more substantially restricted
premorbid affect, odd beliefs, and odd speech (schizoid and
schizotypal traits) have been found in EOS than in adult-
onset schizophrenia [51]. Substantial percentages of patients
with EOS have been found to have a chronic form of the
illness [33, 44] with a poor long-term psychosocial outcome
[15, 44] and with more severe social and educational
impairments than non-schizophrenic psychoses [25].
Deficits in attention, working memory, and verbal
learning and memory, but not in intelligence, have been
found to be associated with short-term functional outcome
in EOS [9]. Nevertheless, intelligence is an important
aspect of cognitive functioning in EOS and early onset
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schizophrenia spectrum disorders because intelligence
deficits may explain deficits in planning [34] and working
memory [49] that are associated with the disorder. Intelli-
gence deficits, as reflected in significantly lower full scale
intelligence quotient (FSIQ), verbal intelligence quotient
(VIQ), and performance intelligence quotient (PIQ) have
been observed in patients with EOS at the time of their first
episode [12, 54]. Significant deficits in FSIQ and PIQ have
also been found in patients with recent-onset EOS [34].
Using prorated IQ estimates based on a subset of an IQ test
battery, marginally [32] or significantly lower intellectual
performance has been observed in patients with EOS [40,
43] as well as in patients with early onset schizophrenia
spectrum disorders [20, 49]. In addition, a study reports the
mean FSIQ in EOS to be 1.6 SD below the population
mean [38]. However, the intelligence deficits in EOS are
not significantly different from samples of other psychotic
patients [12, 35, 38]. When compared with non-psychotic
psychiatric disorders, significantly lower PIQ were
observed in a sample of adolescent patients with schizo-
phrenia or other psychoses [19]. Based on the information
from studies that include healthy controls and exclude
patients with mental retardation, we calculated effect sizes
for intelligence deficits in EOS. With regard to FSIQ,
Cohen’s d was in the order of 1.77 [54], 1.61 [12], to 0.90
[34]; and with regard to brief IQ estimates, Cohen’s d
varied from 2.18 [43], 1.37 [20], 1.18 [40], to 0.56 [32].
Despite the differences in exclusion criteria and IQ mea-
sures, these findings point to substantial intelligence defi-
cits in young patients with EOS.
A recently published controlled longitudinal study found
a significant increase in a composite measure of global
cognitive function over a 2-year follow-up period in a
mixed group of patients with EOS or other psychosis
and the control group [37]. Regarding development of
intelligence, premorbid intellectual performance deficits
aggravate around the time of onset of very early onset
schizophrenia also referred to as childhood onset schizo-
phrenia (COS; onset by age 12), and a mean loss of 9.96
FSIQ points has been observed in the period from 2 years
before illness onset to 1.7 years after [16]. The first pro-
spective longitudinal study [7] of the course of intelligence
impairment in patients with COS found a significant
decline in post-psychotic FSIQ from baseline testing at
12.3 years of age over a mean retest interval of 2.9 years.
In contrast, a later study of a larger cohort of patients with
COS, including the previous sample of patients, found no
decline in mean FSIQ across multiple follow-up assess-
ments, with approximately 2-year intervals across the
2–8? years follow-up period. This seems to reflect long-
term stabilization of FSIQ starting about 2 years after
illness onset and continuing during adolescent and early
adult years up to 13? years after illness onset [16]. A
recent longitudinal study used a case–control design to
assess the development of deficits in several domains of
cognitive functioning, including intelligence, in adolescent
patients with EOS using two time points of assessments
with a mean interval of 4 years. A statistically significant,
but relatively small improvement in mean FSIQ was found
in patients and controls with no significant between-group
difference in amount of change [14]. These longitudinal
studies used age appropriate versions of Wechsler Intelli-
gence Scales and age appropriate norms that make
assessments of IQ from childhood and well into adulthood
possible. However, comparisons of IQs from different test
versions based on different norms may not permit
unequivocal interpretations.
The objective of the current study was to compare the
development of intelligence in EOS patients from their first
psychotic episode to 5 years post onset with healthy con-
trols and patients who at baseline had been diagnosed with
other psychoses. In effort to avoid some of the interpreta-
tive problems, we administered the same version of the
Wechsler Intelligence Scale at baseline and follow-up
assessments and used the same norms to derive IQs at
baseline and follow-up.
Methods
Sample
At baseline, 48 patients with first episode, non-organic,
psychosis fulfilling the ICD-10 [55] diagnostic criteria
for one of the following diagnoses were recruited:
schizophrenia; persistent delusional disorders; acute and
transient psychotic disorders; schizoaffective disorders;
other non-organic psychotic disorders; mania with psy-
chotic symptoms; bipolar affective disorder (current
episode manic or current episode severe depression with
psychotic symptoms); severe depressive episode with
psychotic symptoms; and schizotypal disorder. Patients
were between 10 and 17 years of age at the time of their
first contact with one of the three child- and adolescent
psychiatric departments in the Copenhagen and Northern
Sjaelland, Denmark. The patient exclusion criteria were a
premorbid lifetime history of mental retardation [35, 43],
the presence of any chronic somatic disease, neurological
illness, severe head injury, compulsory hospitalization,
antipsychotic treatment for more than 6 months, or ful-
fillment of the ICD-10 diagnostic criteria for psychotic
disorder (F1x.5) due to psychoactive substance use. One
patient withdrew during the baseline assessment and one
subject was excluded because of hydrocephalus, leaving 46
patients in the sample. At baseline, participants and parents
were informed about the follow-up study and gave
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informed consent to be contacted for a follow-up assess-
ment. The baseline assessment included age of onset of
psychotic symptoms, severity of psychotic and other psy-
chiatric symptoms, severity of neurocognitive deficits [12]
(significant IQ, memory, attention, and executive function
deficits, but no IQ differential factor profile were found in
EOS patients), and structural brain abnormalities [41]
(significantly larger volumes in the body of right lateral
ventricle was observed in EOS patients).
As the present analysis focus on EOS in the context of
non-affective psychoses, patients diagnosed with schizo-
typal disorder or affective psychoses at baseline were
excluded (see Fig. 1). Some patients were unable to com-
plete the baseline assessment of intelligence due to severe
anxiety, psychotic symptoms, lack of motivation, or they
had not been administered the Wechsler Intelligence Scale
for Children, Third Edition version (WISC-III) [52] or
declined participation in the follow-up study. These and
other sources of attrition resulted in ten patients with a
baseline diagnosis of EOS and eight patients with other
non-organic, non-affective psychoses (EOP) (delusional
disorder (N = 1); acute and transient psychotic disorders
(N = 2); other non-organic psychotic disorders (N = 5))
with complete WISC-III data from baseline and follow-up
in the current patient groups. For a detailed description of
the demographic characteristics see Table 1. At baseline
assessment, one patient with EOS was antipsychotic naı¨ve
while the remaining nine patients (90.0%) were treated
with various types of typical (4 patients) and atypical
antipsychotic medications (5 patients) with a mean treat-
ment duration of 9.6 weeks (SD = 5.7) (see Table 1). At
that time, five of the eight patients with EOP (62.5%) were
treated with various types of typical (1 patient) and atypical
antipsychotic medications (3 patients) (1 patient received
both typical and atypical antipsychotic medications), with a
mean treatment duration of 4.7 weeks (SD = 5.5).
At baseline, healthy controls matched with the 46 patients
on gender and age (within 6 months) were recruited from
schools and institutions in Copenhagen. Exclusion criteria
for controls were a history of psychiatric disorders, mental
retardation, learning disability, chronic somatic or neuro-
logical disease, head injuries, abuse of psychoactive sub-
stances, or a psychotic disorder in any first-degree relatives.
Figure 1 shows the number of controls lost to the different
sources of attrition including the youngest healthy control
subject (age 15 at follow-up) excluded (as an outlier) due to
extreme improvement in performance at follow-up com-
pared with baseline. For a detailed description of the
demographic characteristics, see Table 1.
After complete written and oral description of the fol-
low-up study, written informed consent was obtained from
all subjects and from a parent, if the subject was younger
than 18 years of age. The follow-up study was approved by
the local Ethics Committees and carried out in accordance
with the Helsinki declaration. Follow-up assessments were
carried out on an average 5.5 (SD = 0.4) years after the
baseline study. Patients and controls received a small
financial incentive for their participation.
Assessment of psychopathology
ICD-10 [55] diagnoses at baseline and follow-up were
reached by consensus using the Schedules for Clinical
Assessment in Neuropsychiatry Version 2.1 (SCAN 2.1)
[56] based on the video-monitored interviews. As descri-
bed, two clinical subgroups were created based on the
baseline diagnoses, consisting of EOS (N = 10) and EOP
(N = 8). The severity of psychotic symptoms was assessed
using the Scale for the Assessment of Positive Symptoms
(SAPS) [3] and the Scale for the Assessment of Negative
Symptoms (SANS) [2]. Other psychiatric symptoms were
also assessed, the results of which are beyond the scope of
the current paper and will be presented elsewhere. As
shown in Table 1, psychotic symptoms for all patients were
grouped into the psychoticism, disorganized, and negative
symptom dimensions [4]. The age of onset of fully devel-
oped psychotic symptoms was assessed at baseline based
on the information derived from the Interview for the
Retrospective Assessment of the Onset of Schizophrenia
(IRAOS) [21, 36] administered to patients and parents, as
well as information from other sources. Control subjects
were also interviewed using SCAN 2.1 at follow-up, to rule
out the onset of a psychiatric disorder during the follow-up
period.
Assessment of socioeconomic status
Parental education and occupation at baseline were rated
into six social classes according to criteria described by
Hansen [22]. These classes were organized in three groups
(see Table 1). In addition, parental household income at
baseline was rated into one of three economic status groups
(low, middle, or high).
Assessment of intelligence
Cognitive deficits at baseline were assessed with a com-
prehensive neuropsychological test battery including, mea-
sures of intelligence, attention, executive functions, verbal
memory, as well as cognitive and motor reaction times. At
baseline, the neuropsychological test battery was adminis-
tered by BF and has been described in detail elsewhere [11,
12]. For the purpose of a valid comparison of cognitive
performance over time, the baseline neuropsychological test
battery including WISC-III was re-administered to all sub-
jects at the follow-up assessment. With one exception, the
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neuropsychological tests were administered in the same
fixed order at follow-up as at the baseline assessment.
Additional neuropsychological tests were also administered
at follow-up. To compare the change in IQ from baseline to
follow-up, follow-up WISC-III FSIQ, VIQ, and PIQ were
derived using the baseline norms. Changes in IQ were cal-
culated by subtracting each baseline IQ from the corre-
sponding follow-up IQ. Thus, change in FSIQ, PIQ and VIQ
was used as the unit of measurement of intelligence
development.
The study included one EOS patient who at baseline
obtained an IQ below 70 and, therefore, was co-morbid
with mental retardation and mental or behavioral disorders
due to multiple drug use and use of other psychoactive
substances at baseline and due to the use of alcohol at
follow-up. In addition, the study included one patient with
EOP and co-morbid mental or behavioral disorders due to
the use of cannabinoids at follow-up and one EOS patient,
who at follow-up was treated with anticholinergic medi-
cation, which may impair cognition [45]. Based on the
clinical assessment of JRJ (the interviewer) and self-
reported alcohol and drug use on selected SCAN 2.1 items
[56] at the beginning of every test session, none were
judged intoxicated at the time of neuropsychological test-
ing. The neuropsychological assessment at follow-up was
administered by JRJ (neuropsychologist), who was blind
with regard to the neuropsychological test scores at
baseline.
Fig. 1 Retention of EOS and
EOP patients and healthy
controls from baseline to
follow-up assessment
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Table 1 Demographic and clinical characteristics for patients with EOS or EOP and controls
EOS (N = 10) EOP (N = 8) Controls (N = 35) pa
Mean age at baselineb (SD) (years) 15.5 (1.9) 15.3 (1.4) 15.7 (1.5) 0.693/0.815
Mean age at follow-upc (SD) (years) 21.1 (1.9) 20.6 (1.6) 21.3 (1.6) 0.666/0.579
Mean follow-up interval (SD) (years) 5.6 (0.6) 5.3 (0.3) 5.6 (0.3) 0.898/0.288
Gender (female/male) 6/4 4/4 20/15 0.872/0.671
Education at baselined (SD) (years) 8.2 (1.9) 8.5 (1.1) 9.3 (1.7) 0.095/0.723
Antipsychotic treatment
Baseline (medicated/drug naı¨ve)e 9/1 5/3
Follow-up (medicated/not medicated)f 5/5 1/7
Parental education/occupationg
Academic/bachelor 20.0% 62.5% 54.3%
Expert/skilled 50.0% 37.5% 45.7%
Unskilled/unemployed 30.0% 0.0% 0.0% 0.002/0.099
Parental income (household)g
High income 40.0% 37.5% 82.9%
Middle income 40.0% 37.5% 11.4%
Low income 20.0% 25.0% 5.7% 0.026/0.968
Mean age at onset of psychotic symptoms (years) (SD) 11.9 (3.6) 13.0 (4.0) /0.544
ph
Mean psychoticism dimensioni,l (SD)
Baseline 3.8 (1.0) 2.9 (0.7)
Follow-up 2.3 (1.3) 0.8 (0.9) 0.014/0.001
Mean disorganization dimensionj,l (SD)
Baseline 1.1 (1.0) 1.2 (1.3)
Follow-up 1.2 (1.3) 0.3 (0.6) 0.757/0.036
Mean negative symptom dimensionk,l (SD)
Baseline 2.6 (0.9) 2.1 (0.6)
Follow-up 2.0 (1.3) 1.5 (0.8) 0.180/0.157
a EOS group versus control group/EOS group versus EOP group
b Age range at the time of neuropsychological testing at baseline, EOS: 11–17 years, EOP: 13–17 years, and controls: 12–18 years
c Age range at the time of neuropsychological testing at follow-up, EOS: 17–23 years, EOP: 18–22 years, and controls: 17–23 years
d I.e. the number years of school attendance, ranges: EOS (N = 9): 4–10 years, EOP: 7–10 years, controls: 6–12 years
e EOS: 1 patient zuclopenthixol daily dose (dd) 8 mg; 1 patient pimozide dd 4 mg and chlorprothixene dd 15 mg; 1 patient risperidone dd 1 mg
and olanzapine dd 5 mg; 2 patients risperidone dd 2 mg; 1 patient risperidone dd 3 mg; 1 patient perphenazine dd 12 mg; 1 patient perphenazine
dd 16 mg; 1 patient olanzapine dd 20 mg. EOP: 1 patient zuclopenthixol dd 4 mg and olanzapine dd 17.5 mg; 1 patient risperidone dd 2 mg; 1
patient risperidone dd 3 mg; 1 patient olanzapine dd 7.5 mg; 1 patient chlorprothixene dd unknown
f EOS: 1 patient flupenthixole decanoate dose unknown (every 2 weeks) and haloperidole daily dose (dd) 4 mg; 1 patient levomepromazine dd
100 mg and quetiapine dd 400 mg and risperidone (Risperdal Consta) 50 mg (every 2 weeks); 1 patient risperidone dd 1 mg; 1 patient
quetiapine dd 450 mg; 1 patient perphenazine decanoate 108 mg (every 2 weeks). EOP: 1 patient clozapine dd 250 mg
g Frequency within patient- and control group at baseline
h EOS baseline rating versus follow-up rating/EOP baseline rating versus follow-up rating
i (
P
global rating of severity of hallucinations score; global rating of severity of delusions score)/2
j (
P
global rating of severity of bizarre behavior score; global rating of positive formal thought disorder score; inappropriate affect item rating
score)/3
k (
P
global rating of affective flattening score; global rating of alogia score; global rating of avolition–apathy score; global rating of anhedonia–
asociality score)/4
l 0 = none; 1 = questionable; 2 = mild; 3 = moderate; 4 = marked; 5 = severe
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Statistical analyses
Univariate analyses were conducted using SPSS 11.0. The
v2 test was used for comparison of nominal data between
independent groups. The normality of distributions of IQs
and change in IQs was confirmed using Shapiro–Wilk tests.
Independent samples t tests were used to compare data
from independent groups, whereas paired sample t tests
were used to compare within-group data between baseline
and follow-up. The analysis of covariance (ANCOVA)
with FSIQ at baseline as the covariate was used to compare
IQ change between EOS patients and healthy controls.
ANCOVA with FSIQ, negative, and disorganization
symptom severity ratings at baseline as covariates was also
used to compare change in IQ between EOS and EOP
patients. Pearson correlation was calculated to evaluate
possible relations between symptom severity at baseline
and change in IQs over time in EOS patients as well as to
evaluate cross-sectional relations between symptom
severity and IQs at baseline and follow-up. Finally, Pearson
correlation was calculated to assess the degree of stability
of FSIQ over time in EOS and healthy controls. Most
symptom variables had skewed distributions and for
these variables, all analyses were repeated using relevant
rank tests (Mann–Whitney, Wilcoxon and Spearman
correlations).
Owing to the small sample sizes and increased risk for
type II errors, we did not correct for multiple comparisons.
Significance level was set at the 0.05 level.
Results
Psychopathology and sociodemographics
At follow-up, the baseline diagnosis of schizophrenia was
confirmed in all cases in the EOS group. In contrast,
diagnostic instability was highly prevalent in the EOP
group where the baseline diagnoses were changed in 87.5%
of the cases. Five of the 8 EOP patients [62.5%) were
diagnosed with a non-psychotic disorder or no psychiatric
disorder at follow-up (schizophrenia (N = 1); delusional
disorder (N = 1); other non-organic psychotic disorders
(N = 1); moderate depressive episode (N = 1); recurrent
depressive disorder, current episode moderate (N = 1);
panic disorder (N = 1); disturbance of activity and atten-
tion (N = 1); examination and observation for other reason
(N = 1)]. Demographic and clinical characteristics of the
follow-up samples are described in Table 1. In the EOS
group, the average age of the first psychotic symptoms was
11.9 (SD = 3.6) years. Table 1 also shows that the
psychoticism dimension severity ratings improved signifi-
cantly in the EOS group from baseline to follow-up,
whereas no significant differences were observed regarding
disorganization and negative symptom dimension severity
ratings over that time period (Wilcoxon tests confirmed
these results). Fifty percent of EOS patients and 12.5% of
EOP patients reported being treated with antipsychotic
medications (2 EOS patients with typical antipsychotic
medications; 2 EOS patients and 1 EOP patient with
atypical antipsychotic medications; 1 EOS patient with
both types of antipsychotic medications) at the time of the
follow-up assessment (see Table 1). Since the baseline
assessment, 20% of EOS patients and 12.5% of EOP
patients reported having been continuously treated with
antipsychotic medications. One EOS patient also received
anticholinergic treatment at follow-up.
No significant differences in background characteristics
were found between the EOS and EOP groups (see
Table 1). No significant differences were found between
these groups regarding negative and disorganization
symptom severity at baseline, while a trend was observed
for psychoticism symptom severity (significant for the
Mann–Whitney U test).
Patients with EOS and healthy controls did not differ
regarding age and gender distribution, but parental income
and education/occupation differed significantly between
the groups.
Intelligence scores
IQs were significantly lower in EOS than in the controls at
both baseline and follow-up assessments (see Table 2). For
the EOS group paired t tests revealed no significant dif-
ference between baseline and follow-up for any of the three
IQs. For the controls, statistically significant increases in
FSIQ (t = 12.26, df = 34, p \ 0.001), VIQ (t = 6.98,
df = 34, p \ 0.001), and PIQ score (t = 11.67, df = 34,
p \ 0.001) were seen during the follow-up interval.
Table 3 shows a significant difference between the EOS
and the control group in mean change in FSIQ, whereas the
between-group difference in mean change in VIQ and PIQ
were only marginally significant. Preliminary analyses did
not reveal any significant or substantial correlations
between baseline FSIQ and change in any IQ in the EOS or
the healthy control group, but because of the highly sig-
nificant between-group difference in mean FSIQ at base-
line, ANCOVA was conducted with baseline FSIQ as
covariate. This analysis revealed a significant difference
between EOS and the healthy controls with respect to mean
change in FSIQ and VIQ, but not regarding mean change in
PIQ. The adjusted mean change in IQ, 95% confidence
intervals, and p values are shown in Table 3. Separate
exclusion of the EOS patient with co-morbid mental retar-
dation and a substance use disorder and the EOS patient
treated with anticholinergic medication at follow-up, did
346 Eur Child Adolesc Psychiatry (2010) 19:341–351
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not change the statistical significance of the unadjusted or
baseline FSIQ adjusted comparisons of mean FSIQ change
between the remaining nine EOS patients and controls.
Parental baseline education/occupation and household
income did not significantly predict mean change in any IQ
and they were consequently not included as covariates in
the statistical models.
Regarding the stability of FSIQ over the time interval,
Pearson r = 0.87 (p = 0.001) in EOS patients and
r = 0.85 (p \ 0.001) in healthy controls.
No significant differences in IQs at baseline or follow-up
were observed between EOS and EOP groups (see Table 2).
In contrast to the EOS group, significant increase at follow-
up was shown in the EOP group regarding FSIQ (t = 5.12,
df = 7, p = 0.001), VIQ (t = 2.99, df = 7, p = 0.020), and
PIQ (t = 4.36, df = 7, p = 0.003). T tests showed no sig-
nificant difference in any IQ change score between the EOS
and EOP groups (see Table 4). Adjusting for FSIQ, nega-
tive, and disorganized symptom severity at baseline, the
between-group difference in mean change in FSIQ, VIQ,
and PIQ remained non-significant (see Table 4). The
adjusted mean changes in IQs are also shown in Table 4.
After exclusion of one EOS and one EOP patient with sub-
stance use disorders, the difference in mean change in FSIQ
between the remaining EOS and EOP patients was still non-
significant (t = -1.10, df = 14, p = 0.290) and confirmed
after adjusting for baseline FSIQ, negative, and disorganized
symptom severity (F(1,11) = 0.78, p = 0.396). After exclu-
sion of the EOS patient treated with an anticholinergic
medication, the difference in mean change in FSIQ between
the remaining EOS and EOP patients was still non-signifi-
cant (t = -1.51, df = 15, p = 0.152) and confirmed after
adjusting for baseline FSIQ, negative, and disorganized
symptom severity (F(1,12) = 1.77, p = 0.208).
Correlations between IQ and psychopathology ratings
In the EOS sample, only modest and non-significant cor-
relations were observed between change in FSIQ, VIQ, and
PIQ over time and severity of negative and disorganization
symptoms at baseline (these results were confirmed using
Spearman’s rho).
At baseline, no cross-sectional correlation coefficients
between the three IQs and the three symptom dimension
severity ratings obtained statistically significance. These
correlation coefficients were of modest size and five of the
nine were even positive (similar results were found when
using Spearman’s rho). At follow-up, all cross-sectional
correlation coefficients between the three IQs and the three
symptom dimension severity were statistically non-signifi-
cant and negative. The correlation coefficients between
negative symptom severity and IQs were in the medium to
large range. The correlation coefficients between IQs and
psychoticism symptom severity were small, whereas they
were in the small to large ranges regarding disorganization
symptom severity and IQs. Somewhat similar results were
found when using the non-parametric Spearman’s rho,
although the correlation between the follow-up negative
symptom severity and FSIQ attained statistical significance
(Spearman’s rho = -0.65, p = 0.043). In addition, the
follow-up disorganization symptom severity and PIQ was
statistically significant (Spearman’s rho = -0.66, p =
0.038), whereas no significant correlations between follow-
up psychoticism symptom severity and IQs were found,
similarly to the parametric correlations.
Table 2 Mean FSIQ, VIQ, and PIQ at baseline for the EOS, EOP,
and control group and equivalent ‘FSIQ’, ‘VIQ’, and ‘PIQ’ based on
the same baseline norms at follow-up
EOS
(N = 10)
EOP
(N = 8)
Controls
(N = 35)
pa
Mean (SD) Mean (SD) Mean (SD)
Baseline
FSIQ 87.4 (14.5) 89.0 (13.1) 110.1 (12.0) \0.001/0.812
VIQ 87.0 (15.8) 90.4 (15.6) 108.3 (13.9) \0.001/0.657
PIQ 91.0 (15.7) 89.9 (15.0) 110.0 (11.8) \0.001/0.880
Follow-up
‘FSIQ’ 93.1 (20.5) 101.8 (13.8) 124.9 (13.3) \0.001/0.324
‘VIQ’ 91.4 (18.1) 97.0 (18.7) 118.5 (13.6) \0.001/0.529
‘PIQ’ 97.1 (24.0) 107.3 (8.0) 126.5 (13.2) 0.004/0.235
a Independent samples t test of EOS group versus control group/EOS
group versus EOP group
Table 3 Unadjusted and adjusted comparisons of mean change in FSIQ, VIQ, and PIQ between EOS patients and controls
EOS (N = 10) Controls (N = 35) pa pb
Mean (SD) Adjusted meanc Mean (SD) Adjusted meanc
FSIQ 5.7 (10.8) 5.9 (-0.3–12.2) 14.8 (7.1) 14.7 (11.8–17.7) 0.003 0.021
VIQ 4.4 (7.5) 2.3 (-4.1–8.8) 10.1 (8.6) 10.7 (7.7–13.8) 0.063 0.031
PIQ 6.1 (17.4) 8.8 (0.4–17.2) 16.5 (8.4) 15.7 (11.8–19.7) 0.096 0.163
a Independent samples t tests; unadjusted
b Analyses of covariance; adjusted for baseline FSIQ
c 95% confidence interval
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Discussion
To our knowledge, this is the first study in which identical
Wechsler IQ test version and baseline norms were used at
both baseline and follow-up assessments in early onset
schizophrenia patients. This strategy attempts to avoid
possible confounding associated with comparison of IQs
derived from different IQ test versions and norms. Using this
approach, we compared the IQ changes in EOS patients from
first episode to 5 years post onset with healthy controls and
patients who at baseline had been diagnosed with other
psychoses. All patients had received standard treatment in
the 5 years since illness onset, and the EOS patients were all
diagnostically stable (i.e., still diagnosed with schizophre-
nia) at 5 year follow-up. In comparison, diagnoses in the
EOP group were much less stable. The average change in
FSIQ was significantly smaller in the EOS group than in the
healthy control group, while the results were only margin-
ally significant for mean change in VIQ. When adjusting for
FSIQ at baseline, statistically significant between-group
differences were observed for mean change in both FSIQ
and VIQ. With regard to change in PIQ, both unadjusted and
baseline FSIQ adjusted analyses revealed non-significant
differences between EOS and the control group. Given the
small sample size, statistical power is an obvious problem,
and the results for change in PIQ are ambiguous. The lack of
statistical significance in mean change in PIQ may reflect a
type II error given the relatively large observed differences
in mean PIQ increase (cf. Table 3), but the pattern of IQ
changes suggests that when compared with healthy controls,
EOS patients show less serious developmental deficits with
the ‘non-verbal’ performance subtests than with the verbal
subtests. We interpret this pattern of results as suggesting an
abnormally small average growth in general and verbal
intelligence during the first 5 years after full clinical pre-
sentation in EOS patients. If perfectly equivalent age-rele-
vant IQ test versions and norms had been used, the observed
subnormal mean gain in test scores in EOS patients during
this illness phase would most likely have led to a decline in
mean FSIQ at follow-up. This mean FSIQ decline would not
reflect deterioration of acquired intellectual knowledge and
skills, but subnormal learning of new information and skills
given the improvement, albeit non-significant, in mean
intellectual performance observed in our EOS patient group.
Thus, our results did not support post-onset deterioration in
intelligence, and we interpret our results as in accordance
with the neurodevelopmental model of schizophrenia [53].
The abnormally low increase in mean FSIQ and VIQ in
our sample of EOS patients seems to contrast with the
earlier findings of relative stability in age-corrected FSIQ
persisting up to 13? years after the onset of psychosis [16].
This finding of long-term stability in FSIQ is corroborated
by similar, minor and statistical significant improvements
in age-corrected FSIQ in EOS patients and controls over a
mean interval of 4 years [14]. A possible explanation for
the different findings may be methodological since previ-
ous longitudinal studies of intelligence in EOS and COS
administered age appropriate childhood and adult IQ test
versions. In contrast, we administered the same childhood
IQ test at both assessments and used the baseline norms at
follow-up to avoid possible differences between assess-
ment methods and norms. Ceiling effects may be a
potential problem associated with re-administration of a
childhood IQ test version to young adults, but none of the
patients with EOS or EOP obtained maximum scores in
any WISC-III subtest at follow-up. However, 11.4% and
31.4% of the healthy controls obtained maximum scores in
at least one verbal subtest and one non-verbal subtest,
respectively, and this uneven distribution of ceiling effects
may have created a bias toward underestimating the mag-
nitude of the between-group differences in change of
intellectual performance.
In contrast to Gochman et al. [16] and Frangou et al.
[14], we included one EOS patient with both mental
retardation and mental or behavioral disorders due to
multiple drug use and use of other psychoactive substances
at baseline and due to use of alcohol at follow-up. How-
ever, previous studies found that approximately 30% of
early onset schizophrenic patients are mentally retarded
[26], and consequently mentally retarded patients should be
included in representative samples of early onset, first
presentation schizophrenia patients.
Table 4 Unadjusted and adjusted comparisons of mean change in FSIQ, VIQ, and PIQ between EOS and EOP patients
EOS (N = 10) EOP (N = 8) pa pb
Mean (SD) Adjusted meanc Mean (SD) Adjusted meanc
FSIQ 5.7 (10.8) 5.7 (-1.4–12.9) 12.8 (7.0) 12.7 (4.7–20.8) 0.131 0.191
VIQ 4.4 (7.5) 4.8 (-0.5–10.1) 6.6 (6.3) 6.1 (0.2–12.1) 0.513 0.730
PIQ 6.1 (17.4) 5.7 (-5.7–17.1) 17.4 (11.3) 17.8 (5.1–30.6) 0.133 0.159
a Independent samples t test
b Analyses of covariance; adjusted for baseline FSIQ, negative and disorganization symptom severity
c 95% confidence interval
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The significant increase in IQs observed in healthy
controls cannot be explained by practice effects given the
5-year time interval between the two assessments, as non-
significant and negligible differences in mean WISC-III
FSIQ and PIQ have previously been demonstrated over a
shorter interval [8]. The small increases in IQs in EOS
patients may to some extent reflect test performance factors
rather than the amount of growth in intelligence. Possible
negative influences on IQ test performance from attention-
and verbal memory deficits associated with EOS may have
worsened during the follow-up interval, as significant
declines in immediate verbal memory [14] and attention
have been observed after the onset of EOS [14, 39]. Also,
using a cross-sectional design, attention deficits in EOS
have been shown to worsen with increasing age [46]. Thus,
deterioration of specific cognitive functions may have
introduced bias toward low IQ test performance at follow-
up and consequently led to an underestimation of the true
gain in intelligence in EOS patients over time. However,
decline in these cognitive functions may also interfere with
the ability of EOS patients to acquire new information and
skills and thus cause real reduction in intelligence growth.
Evaluating the validity of IQs in the context of psycho-
pathological symptom severity at the time of test adminis-
tration, we interpret the baseline pattern of non-significant
and predominantly small correlations between severity of
symptom dimensions and IQs as reflecting small effects of
psychopathological symptom severity on intellectual per-
formance. At the 5-year follow-up assessment, significant
correlations between IQs and negative and disorganization
symptom severity were found, whereas IQs appear to be
relatively independent of psychotic symptom severity.
Given the questionable and mild mean negative and disor-
ganization symptom severity at follow-up, we conclude that
the IQs obtained in the chronic phase of this EOS sample are
essentially unbiased by schizophrenia symptoms.
Another possible influential factor in relation to the
development of intelligence in EOS is antipsychotic medi-
cation, which was not investigated in this naturalistic study,
as it was impossible to control the medication administered
over a 5-year period. The influence from antipsychotic
medications on intellectual performance may be of minor
importance, as the improvements in overall cognitive
function associated with atypical antipsychotic treatment are
of relatively small magnitude [31, 59], and some of the
cognitive improvements found in other studies have been
suggested to be caused by practice effects [18] and/or
expectation biases [31]. In addition, a meta-analysis found
no relationship between neuroleptic dose and IQ effect sizes
in adults [23]. The treatment in our EOS sample at follow-up
included various first-generation antipsychotic medications
including perphenazine that has been found to have only
small effects on overall cognitive function, similar to the
effects of atypical antipsychotic medications [31]. However,
as 90% of the EOS sample was treated with antipsychotic
medication at baseline and only 50% at follow-up assess-
ment, we cannot exclude the possibility that the difference in
mean FSIQ and VIQ change between EOS patients and
healthy controls may have been influenced by the cessation
of antipsychotic medication. However, the high FSIQ retest
coefficient observed in our EOS patients indicates IQ sta-
bility similar to the stability in healthy controls, and this
finding also suggest that FSIQ is relatively unbiased in both
the early and chronic EOS phase.
A significant IQ decline has been reported around the
time of onset of COS [16] and adult schizophrenia [58]. As
the baseline assessment in our study took place at the time
of the first psychotic episode, it is possible that onset-
related decline in intelligence continued in some patients
after baseline assessment. However, considering the mean
age of 11.9 years at onset of psychotic symptoms in the
EOS patients and the mean age of 15.5 years at the base-
line assessment (a mean interval of 3.6 years), the effects
of onset-related IQ decline is likely to be negligible.
One of the limitations of the study is the lack of admin-
istration of urine drug detection tests that are preferable to
clinical assessment and self-reported information on alcohol
and drug use. The small patient sample sizes clearly limit the
generalizability of our results and reduce the statistical
power to detect changes in intellectual performance. Sta-
tistical significant differences were found between patients
and controls despite the small sample sizes, but the lack of
statistically significant differences in mean FSIQ and PIQ
changes between EOS and EOP groups must be interpreted
with caution due to the small sample sizes, as the results
likely may reflect a type II error given the relatively large
observed differences in mean FSIQ and PIQ increases (cf.
Table 4). Comparing change in IQs between EOS and EOP
groups, baseline negative and disorganization symptom
severity ratings were thought to be appropriate covariates in
addition to FSIQ because they have been found to be asso-
ciated with intellectual performance deficits [6, 10, 27]. In
addition, negative but not positive symptomatology is
associated with cognitive performance in EOS [5].
The observed positive predictive value of 100% for early
onset schizophrenia in our EOS subgroup points to high
diagnostic stability. High long-term stability for early onset
schizophrenia has also been found in both studies with fol-
low-up assessment blind to initial diagnoses [24, 25] and
studies without blind re-assessment [30]. Nevertheless,
substantially lower long-term diagnostic stability for early
onset schizophrenia has also been reported [48]. The sta-
bility of Other nonorganic psychotic disorders (F28) is low,
as indicated by a positive-predictive value of 20%. This
estimate appears in line with the low long-term positive
predictive value of 0% for early onset atypical psychosis
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[25], 33% for early onset psychosis not otherwise specified
(NOS) [30], and 17% for early onset psychosis NOS in a
study that probably did not include blind re-assessment [13].
Our results suggest that the diagnostic distinction between
schizophrenia and other non-organic psychotic disorders
(F28) at illness onset is of long-term clinical significance in
early onset patients.
In healthy children and adolescents, FSIQ is associated
with whole-brain gray matter volume [42, 57] and with left
and right parietal, frontal, temporal lobe, and cingulate
gray matter volumes [57]. In COS patients, an abnormal
total, frontal, temporal, and parietal gray matter reduction
has been demonstrated during adolescence without signif-
icant change in mean FSIQ [17]. Larger gray matter loss
rates have also been found in superior medial frontal cor-
tices and left cingulate cortex in COS patients compared
with controls and FSIQ was unrelated to the gray matter
volumes at baseline and follow-up [50]. Larger gray matter
loss rates in parietal, temporal, and frontal cortices have
also been found in COS patients when compared with
controls and the overall tissue deficit correlated with FSIQ
at follow-up [47]. Regarding adolescent-onset schizophre-
nia, brain volume abnormalities have been demonstrated,
but no significant volume changes were found during late
adolescence [28, 29]. These studies have not explored the
possible associations between cognitive performance and
brain structure volume, and whether subnormal growth in
intelligence in the current EOS sample is related to struc-
tural brain volume changes will be the subject of further
analyses.
Conclusion
Using an identical Wechsler IQ test version and the same
norms at both baseline and follow-up assessments in this
controlled longitudinal study, we demonstrated abnormally
small growth in general and verbal intelligence in EOS
patients during the 5 years after their first psychotic epi-
sode. These results suggest abnormally slow acquisition of
new intellectual information and skills in early onset
schizophrenia rather than deterioration of intelligence, and
they support a neurodevelopmental model of early onset
schizophrenia. In contrast, development in non-verbal
intelligence in EOS was not significantly different from
that of healthy controls, but this finding as well as the lack
of significant difference in growth in intelligence between
EOS and EOP patients must be interpreted with caution
due to limited sample sizes.
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